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Abstract
Background: The rising demand for chronic disease treatment and the barriers to accessing these medicines have
led to the development of novel models for distributing medicines in South Africa’s public sector, including
distribution away from health centres, known as community-based distribution (CBD). In this article, we provide a
typology of CBD models and outline perceived facilitators and barriers to their implementation using an adapted
health systems framework with a view to analysing how future policy decisions on CBD could impact existing
models and the health system as a whole.
Methods: A qualitative exploratory study comprising in-depth interviews and non-participant observations was
conducted between 2012 and 2014 in one province. Study participants consisted of frontline healthcare providers
(HCPs) in the public sector and a few policy, supply chain and public health experts. Observations of processes
occurred at two CBD sites. We conducted deductive analysis guided by the adapted framework.
Results: Models varied in typology ranging from formal (approved by the Department of Health) to informal
(demand-driven) and with or without user-fees. Processes and structures also differed, as did HCPs’ perceptions of
what is appropriate. HCPs perceived that CBD models were largely acceptable to patients and accommodating of
their needs. Affordability of services linked to charging of user-fees was a contested issue, requiring further
exploration. CBD models operated in the absence of formal policy to guide implementation, and this, coupled with
the involvement of non-health professionals, issues regarding medicines handling and storage; and limited patient
counselling raised concerns about the quality of pharmaceutical services being delivered. Policy decisions on each
of the health system elements will likely affect other elements and ultimately influence the structure and
operational modalities of models. In anticipation of a future CBD policy, stakeholders cited the need for a context
specific lens in order to harmonise with current implementation efforts.
Conclusion: A formal policy on CBD is required in an effort to standardise services for quality assurance purposes.
Frontline HCPs should be involved in the development of such policy to ensure that existing arrangements already
working well are not undermined. Further research will seek to contribute towards evidence-based development of
policy and service delivery guidelines for CBD activities in South Africa.
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Background
South Africa shares with the rest of sub-Saharan Africa a
high burden of chronic diseases, including HIV and non-
communicable diseases [1]. This has led to an increasing
demand for medicines for treatment of disease in a con-
text of a weak health system [2]. The increased burden of
disease has illuminated the need for the government to be
more responsive to population needs and to ensure that
people obtain health services (including accessing essential
medicines) without suffering financial hardship. The latter
are in line with principles of universal health coverage
(UHC) [3].
The South African government released the National
Health Insurance (NHI) White Paper in December 2015.
This policy document discusses various health insurance
modalities and reforms aimed at strengthening the country’s
health system. These include: expanding access to pharma-
ceutical products, a primary healthcare re-engineering strat-
egy and establishment of an office of health standards
compliance. Furthermore, it describes a vision of what is re-
quired for the successful implementation of NHI [4].
Against this background, we have witnessed a shift in the
local access to medicines (ATM) domain, from a largely
health facility-based approach to providing medicines for
chronic diseases to novel community-based distribution
(CBD) models, also referred to as alternative distribution or
out-of-clinic models [5]. While the term “distribution”
within the broader medicine supply chain context encom-
passes ordering, transportation and logistics management
at various levels [6], its use in this article is confined to lo-
gistics activities to get patient-ready pre-packaged medi-
cines to patients. This has been referred by some authors as
the “last mile”, where services are delivered to patients and
often at the most vulnerable stage of distribution [7].
CBD models use community halls and similar gathering
places as sites for medicine distribution, exploiting the
proximity of these venues to patients’ homes. Sometimes,
they also include home deliveries. These models are geared
towards addressing various supply- and demand-side
barriers to accessing medicines [8]. Such barriers include:
long waiting times, overburdened health centres which dis-
courage patients from collecting medicines and reducing
travel costs to distant health facilities. Furthermore, CBD
models can allow for task-shifting to mid-level cadres or
even to expert patients in order to address human resource
shortages [9, 10]. The latter is facilitated by the choice of
target beneficiaries, i.e. stable patients not requiring regular
contact with a healthcare provider (HCP). Such patients
can be sufficiently empowered to self-manage [11] and have
six-monthly consultations. CBD is not only recognised in
South Africa as an interesting solution to restricted access
to medicines [12, 13], but in many other developing coun-
tries, [14–16] including Mozambique [5, 17–19], Zambia
[20] and Kenya [21]. CBD models are driven by non-
governmental organisations (NGOs) in the majority of
cases.
While CBD is gaining momentum in South Africa, the
range of models and the pace of implementation are
variable across provinces. This could be explained in
part by the health system’s governance structure, which
allow provinces a fair degree of autonomy in the admin-
istration of health services [22]. The Western Cape is
one province where CBD has been widely implemented.
In this province, CBD falls under the umbrella of
community-based services, an important component of
the broader primary healthcare (PHC) platform that fea-
tures in the provincial strategy for health, Healthcare
2030 [23]. CBD is facilitated by centralised dispensing of
patient-ready medicine packages by a private distributor
to health facilities [24–27]. These packages can easily be
transported to CBD points.
This article draws on selected findings from a broad
exploratory study commissioned by the Western Cape
Department of Health (WCDoH) to improve access to
medicines (ATM). The overall study sought to identify
strategies to address the challenge of missed appoint-
ments among patients with chronic diseases in the
metropolitan district of Cape Town [24]. We also sought
to understand the structure of ATM strategies and the
facilitators and barriers to effective implementation. We
targeted frontline healthcare providers (HCPs), most of
whom engage with patients on a regular basis. These
stakeholders have a critical role in the attainment of pol-
icy outcomes yet their role is often overlooked [28, 29].
Our research showed that many HCPs identified CBD
(among a few others) as an existing innovative strategy
for ensuring that medicines reach patients. However,
they also cited challenges, of which the most important
was the lack of policy to govern CBD activities even
though their implementation was actually underway.
The implication was that certain issues related to CBD
could be open to multiple interpretations. We discov-
ered early on that governing CBD activities was far from
being simple, given that these are “non-traditional”
mechanisms for medicines distribution.
As the development of a CBD policy is a current priority
in South Africa, in this article we seek to contribute to the
policy-making process by exploring how CBD models cur-
rently operate in the Western Cape Province’s local health
system and identifying the perspectives of frontline HCPs
regarding CBD models. In order to provide evidence that
could inform policy design, we have adapted the health
systems framework of van Olmen et al. (the framework)
[30] as an analytical tool for the following reasons:
a) Its ability to assist us to identify and discuss the key
elements of CBD models (e.g. medicines supply,
human resources, infrastructure and population) and
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to draw the interconnections between the elements
which will be of relevance to the design of CBD
policy;
b) Its ability to frame CBD operations within the
context of the broader health system;
c) The importance it attaches to values and principles
in policy-making [22].
d) Its recognition of health systems as social systems
which comprise people and organisations, and their
interactions with others. As such, actors’ values,
interests, norms and relationships also influence the
ultimate character of the system [31].
In this article we use the framework to provide a sys-
tematic description of CBD models and to illustrate how
the configuration of the elements in each CBD model
contributes to its effectiveness. Finally, we explore how
our findings could inform the development of an




This exploratory qualitative study was conducted be-
tween 2012 and 2014 in the metropolitan district of
Cape Town, which has the greatest proportion of
patients and the greatest pressure on health services in
the Western Cape Province [24, 25].
Data collection
We used in-depth interviews, non-participant observa-
tions of two CBD sessions and document review as the
data collection methods for this study.
Key informants
For this article, we drew from 45 in-depth interviews,
which were conducted by the first author using a semi-
structured interview guide. We purposively sampled infor-
mants who were most knowledgeable about the issues of
interest from the following categories: (1) frontline HCPs,
including doctors, nurses, pharmacists and pharmacist’s
assistants (PAs) from four PHC facilities, (2) policy
makers, (3) sub-district and provincial managers from the
WCDoH, (4) private sector pharmacists, (5) academics
with expertise in pharmaceutical policy and public health
and (6) NGO staff (Table 1). Interviews were conducted in
English and each interview lasted about one hour. All the
interviews were conducted at a place convenient for the
respondents, i.e. their place of work. Where possible, in-
terviews were recorded; alternatively, notes were taken.
Three participants refused to be recorded as a matter of
preference. Once no information was generated from the
interviews and saturation was reached, no further inter-
views were conducted.
Non-participant observations
The first author conducted observations on two occasions.
The first session was for distribution of HIV treatment
and another for distribution of medicines for non-
communicable diseases (e.g. diabetes and hypertension).
Both sessions took place in Khayelitsha, one of the largest
townships in South Africa. During observations, the first
author took note of patient-patient and patient-provider
interactions and the process in general. Other items that
were recorded included the queries that were posed by
patients and any information related to patients’ know-
ledge about their medication.
Document review
We reviewed guidelines and standard operating proce-
dures for CBD in order to understand how the models
are currently implemented [32, 33].
Data analysis
The recordings were transcribed verbatim and deductive
analysis was applied. We sought for : (a) structure of CBD
models, and used the main elements of the analytical
framework of van Olmen et al. [30], (Fig. 1) which links the
central elements required for models to function optimally
i.e. resources (medicines, human resources, infrastructure, fi-
nancing, monitoring and evaluation) to the performance of
the service delivery platforms. All these elements require
good governance (policies, regulatory frameworks) and lead-
ership, taking into account the population’s needs and de-
mands [34] to attain ATM in terms of its different access
dimensions or outcomes; i.e.: availability, affordability, acces-
sibility, acceptability and quality) [35, 36] and ultimately im-
proved health status and social and financial protection.
Access outcomes can be broadly defined as follows:
 acceptability: fit between clients and providers’
mutual expectations and appropriateness of care;
Table 1 Respondents’ breakdown by professional category
Category Number of
respondents
National level policy maker in pharmaceutical
regulation
1
Senior provincial directors and policy makers 5
Academic in public health 1
Provincial managers of the medicines supply chain 2
Mid-level managers (sub-structure pharmacists;
primary healthcare managers)
4
Frontline health workers (clinicians, health
promoters, NGO workers)
28
Private sector pharmacists 4
Total 45
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 accommodation: fit between organisation of services
and clients’ practical circumstances;
 availability: fit between existing resources and
clients’ needs;
 accessibility: fit between physical location of
healthcare and location of clients;
 affordability: fit between cost of care and ability to
pay [35].
Outcomes are expressed both quantitatively and qualita-
tively by our adopted framework [30]. However, in the ab-
sence of objective outcome- and impact-level data for
CBD models, we assessed selected outcomes only qualita-
tively, from the perspectives of informants. Accessibility is
an inherent design feature of CBD models and as such this
was not assessed. Using data from interviews and observa-
tions, we assessed how models were perceived by infor-
mants and patient engagement with CBD services. Our
assumption was that if models increase ATM, this could
be a proxy for utilisation. In addition, we considered facili-
tators and barriers to effective implementation and context
factors because CBD models are embedded within a
broader health system and these factors can influence out-
comes and goals (Fig. 1). Quality was a cross-cutting issue
addressing the issues of scientifically and medically appro-
priate and good quality services. This is determined by as-
pects such as human resources and good quality
medicines.
Data from document review and observations were
used to triangulate key informant data.
The first author conducted the initial analysis (coding,
retrieving of quotations representative of major themes
and interpretation) using Atlas. TI version 7. Emerging
themes were discussed with selected key informants
through three feedback sessions (participant checking).
Results
This section starts by presenting an overview of how
CBD services are organised (Typology of CBD models)
then presents the remaining findings according to the
elements of the framework (human resources, medicines,
infrastructure and population). Finally, we present our
findings related to governance, taking into account the
implementation context.
Typology of CBD models
From the interviews with key informants, we found vari-
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Fig. 1 Conceptual framework adapted for this study
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in the Western Cape Province. Regarding geographical
spread, some areas had a single model while others had a
combination of models. The mix of models available in an
area was primarily dependant on the presence and
mandate or interests of particular stakeholders whose ac-
tivities tended to be geographically demarcated. However,
they were all linked to nearby PHC facilities for medicines
supply. In this article, we categorised them as formal and
informal as explained below:
I. Formal: Models officially recognised and approved by
the WCDoH. Services were provided free of charge
to the patient. Formally recognised providers were
expected to facilitate referrals and linkage to care for
patients at risk who require consultation with the
health provider. Some models were based on direct
involvement of trained HCPs (i.e. nurses and/or
post-basic pharmacists), while others were driven by
community health workers (CHWs) with some basic
health training, linked to NGOs.
II. Informal: Models driven by entrepreneurs with no
basic training in health. They charged a service fee to
the patient and were not officially recognised by the
WCDoH. Informal providers could be described in two
ways: either operating under the 'approval' of mid-level
management or known anecdotally, but not easily iden-
tifiable. The latter operated on a small-scale and could
not be easily distinguished from a relative or friend col-
lecting medicines on behalf of the patient. At the time of
research, service fees charged by the known informal
providers ranged from ZAR10.00–20.00, which was
equivalent to approximately US$1.00-2.00. It was
unclear how informal providers market their services or
initiate services in the absence of the approval of
senior provincial leadership.
Patient enrolment in all the CBD models was facili-
tated by nurses and health promoters during club
sessions (group-based education), and patients were
asked to provide consent for their information to be
supplied to the service provider of their choice. Table 2
shows the range of models that we identified at our
study sites. We acknowledge that this list may not be ex-
haustive for the Cape Town metropolitan area.
Resources
Human resources
As illustrated in Table 2, task shifting from pharmacists
to other HCPs and Non-Health Professionals (NHPs) is
a common feature in CBD models. There was conten-
tion between participants about the involvement of
NHPs and their permitted scope of practice.
Proponents for task-shifting in CBD models argued
that this mechanism could address existing human re-
source shortages in the South African public sector by
“de-medicalising” treatment to ensure sustainability of
models. Informants cited a situation illustrating lack of
sustainability of medicalised models: a clinical nurse
practitioner was asked to urgently return to the health
facility from a CBD site leaving patients unattended and
necessitating their referral back to the health facility.
Another stakeholder (academic) argued that patient
counselling by pharmacists, though desired, was in most
cases impractical. The informant’s own research showed
that pharmacists in the Western Cape spend an average
of only three minutes (range: 2–4 min) of face-to-face
contact with a patient due to workload pressures. In
light of these health workforce issues, stakeholders sug-
gested the need for greater efforts towards empowering
patients to manage their own therapy thereby reducing
the need for regular contact with HCPs.
Those who opposed involvement of NHPs in CBD cited
their lack of accountability to statutory bodies as a major
concern in delivering pharmaceutical services. This is cur-
rently a grey area in the task-shifting discourse because
Table 2 Overview of models for community based distribution of medicines
Type of model Classification Human resources Financing Beneficiary population
as per disease state
1. Distribution in community
halls, churches, old-age
homes or mobile clinics
Formal Pharmacist’s assistants, nurses Health facility budget therefore
government funding
HIV and/or NCDs
2. Distribution in small
municipal clinics that do
not offer NCD services
Formal Pharmacist’s assistants Health facility budget
therefore government funding
NCDs
3. Home delivery Informal Local social entrepreneurs Out-of-pocket payments NCDs
4. Home delivery or other
community venuesa
Formal Community health workersb A few organisations have international
funding while the rest receive grants
from the Department of Social Development
(DSD) and other local businesses.
NCDs
aPlaces where the elderly meet for skills development and social activities, also termed Chronic Disease of Lifestyle clubs which the WCDoH identified through the DSD
bAttached to NGOs with service level agreements with the WCDoH
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statutory bodies only regulate personnel who are regis-
tered with them.
Other concerns raised by participants related to the cap-
acity of NHPs to: (i) conduct quality assurance (QA) pro-
cesses (e.g. verifying medicines before handing them over
to the patient), (ii) monitor therapeutic outcomes and
(iii) link at-risk patients to appropriate care. These tasks
are outside their scope of practice therefore, perhaps a
more pertinent question is: which tasks should NHPs be
expected to carry out? Many informants argued that QA
processes should be ensured by the Chronic Dispensing
Unit (CDU), a centralised dispensary responsible for dis-
pensing and pre-packing of medicines in the public sector
in this province. If performed optimally by ensuring min-
imal prescribing and dispensing errors, this would elimin-
ate the need for checking parcels at the distribution point
upon issue to patients. With QA processes out of the way,
this would technically not be a full dispensing process,
allowing NHPs to comfortably participate in the process.
It seemed even pharmacists who were responsible for
checking the pre-packed medicine packages felt that the
QA demands were time consuming and detracted from
the intended benefits of both the CDU (which was
established to reduce pharmacists’ workload) and of
CBD (which was established to take the pressure off
health facilities and to improve access for patients).
While some informants mentioned that they would feel
comfortable relying on CHWs to issue medicines that
were already checked at the CDU, some clinicians were
still reluctant. They suggested that CBD activities be
placed under the responsibility of registered pharmacy
mid-level workers known as pharmacist’s assistants (PAs)
as opposed to CHWs. A further suggestion was engage-
ment of private-sector pharmacies to distribute public-
sector medicines. In subsequent years, this model was
proposed under the NHI scheme [37].
Medicines supply management
Our findings show that inefficiencies in procurement (a
macro-level issue) affected medicines availability at the
CDU where dispensing for CBD programmes takes place.
As such, medicines omitted from parcels would require
manual dispensing at health facilities, another reason why
informants were sceptical about NHPs involvement as the
final link to patients. As stated by a senior manager:
“I wouldn’t like at this stage for community health
workers to give medication, because, once in a while,
something is missing, because of the out-of-stock situation.
Now we got a serious situation as well…the Cape Medical
Depot cannot always supply because of change of tender.”
Another contentious issue raised was the handling
and storage of “non-collected” medicines, i.e. parcels
not collected by the patient on the appointment date.
The handling of medicines by untrained personnel and
their storage in transient unregistered sites casts doubt
on the integrity of non-collected medicines and as such,
these medicines are usually disposed of with resultant
cost implications. Informants were of the opinion that
some of these risks could be obviated if sites met mini-
mum standards for medicine storage.
Infrastructure and logistics
Securing reliable venues for CBD activities emerged as
another important aspect of CBD. During the time of
our study, services were interrupted at one site because
it was no longer available for CBD. The PA at the site
expressed concern about the potential loss of confidence
by patients experiencing service disruption. In addition
to securing venues, opening times for the venues needed
careful consideration. This often called for negotiation
with the owners of the venue to ensure that times were
suitable for the patients.
Reliable transportation for medicine delivery to CBD
sites was also identified as a need. Government vehicles
could be requested by PAs linked to formal CBD
models, but this transportation mode was not accessible
to CHWs who often walked to sites and carried the sup-
plies. According to informants, the latter not only posed
security risks and environmental risks for the medicines,
but created inefficiencies for CHWs with home-based
care duties who were often late for CBD activities.
Informal providers used bicycles and this was also feared
to potentially render medicines vulnerable to environ-
mental risks.
Outcomes
Acceptability of CBD models and accommodation to clients’
practical circumstances
We used our observation data related to patient-provider
and patient-patient interactions during the CBD process
to look into the acceptability of the models. Interactions
between patients and providers and between patients were
largely positive. Patients showed no restraint in engaging
with the providers involved in CBD (both HPs and NHPs)
even when they presented late for their appointments. In
some cases, CHWs reported taking the initiative to deliver
medicines to patients’ homes when they failed to collect at
community venues, a means of accommodating patients’
practical circumstances. These deviations from formal
processes were merely acts of goodwill facilitated by posi-
tive patient-provider relationships, but were noted to con-
tribute to acceptability. Furthermore, CHWs reported
using cost-effective social media methods such as the
instant messaging application “WhatsApp” to remind
patients of their appointments and to follow-up with those
who missed appointments. In this regard, the close
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patient-provider interactions allowed for some degree of
patient follow-up where there had been limited to no
follow-up mechanisms in the health system. These experi-
ences also reveal a form of grassroots innovation that
could improve patient retention-in-care in the long-run.
Informants collectively felt that CBD models are suitable
for patients who are empowered to take responsibility for
the management of their illness. From observation during
CBD operations, some patients were able to accurately iden-
tify their medicines, including identifying any missing medi-
cines when there were medicines availability challenges.
Despite the positive aforementioned aspects, there
were some concerns with stigma. At one site (a small
municipal clinic which traditionally offered HIV services
and was later also used as a distribution site for NCD
medicines), patients on ART raised concerns about priv-
acy because their appointments overlapped with patients
enrolled in NCD programmes. With medicine collection
points for ART being distinct, patients with HIV were
easily identifiable and this was a huge concern for those
who had not disclosed to family and friends. This raised
questions about the appropriateness of integrating HIV
and NCDs in the design of CBD models.
At a second site, providers also noticed similar reluc-
tance from clients on ART. The pharmacist’s assistant in
charge of CBD at the site said:
“…we told them that it’s only them who are going
there; there are a lot of offices so no one will know why
you are walking through that building, what you are
going to do there…”
While in principle, patients should be offered the
choice to collect medicines at CBD sites or at the health
facility, in practice there seemed to be pressure to enrol
all patients onto CBD models, because of the perceived
benefits for both the health system and the patients.
Asked if patients had a choice regarding their collection
point, one PA stated “…we don’t prioritise that freedom”.
In their view, once patients experienced the benefits of
CBD, they appreciated the system and in most cases
were no longer interested in the facility-based model.
Affordability to patients: to pay or not to pay for CBD
services?
As stated earlier, the critical difference between the
formal and informal CBD models was that the former
provides services at no charge to the patient while the
latter levies a user-fee. Many stakeholders grappled with
the issue of paid services: some senior managers
expressed disapproval of imposing out-of-pocket pay-
ments on the premise that medication was free and no
direct charges should be introduced to the patients,
while others feared that the absence of regulation on
levying fees could result in patient exploitation. Indeed,
some patients had apparently mentioned to informants
that the services were expensive for them but some
HCPs still argued that paid services were demand-driven
and that many patients were willing to pay for a service
offering convenience. One nurse and PA were of the
opinion that the elderly derived particular benefits since
they often have impaired mobility, lack family and other
support to collect medicine on their behalf and many
stayed in areas that are not served by formal models.
Also, the formal models had limited capacity to serve a
large population. Some respondents felt that paid ser-
vices offset the usual indirect costs for transport fees to
the health facility and thus had no objection to charging
fees for CBD services.
At the time of our study, one of the four study sites had
no history of “fee-for” services, a second site still charged
a fee and the remaining two sites had been mandated to
cease services that attached a fee. Although some frontline
HCPs approved of services levied for a fee at the second
site, senior managers had strong reservations. However,
HCPs reported that some patients still enquired about the
service and attributed increased non-collection of medi-
cines to the management’s decision to stop these paid ser-
vices. One pharmacist elaborated as follows:
“A few years ago, we had a courier service that was
privately run and we had an objection from the
government that it’s unconstitutional to charge
patients from a primary health care level. Then we
stopped it. The patients benefited a lot from it and up
to this day, patients are still asking “When is it coming
back and why can’t we have it back?”, because they
were prepared to pay. But the department said it is
criminal for patients who can’t afford the service. It
didn’t make sense to us but it came from the top level
to be stopped basically, but it was working well and
we were pushing almost 200 parcels a day from the
facility.” [Pharmacist]
In essence, views on paid services were quite diver-
gent, with provincial managers expressing the need to
safeguard patients against exploitation and with some
frontline HCPs indicating that paid for services are
demand-driven and should remain an option to patients.
Governance: Policy and regulatory issues
As stated earlier, for any service delivery model to function
effectively, all health system elements require good govern-
ance in the form of policies and regulatory frameworks
which consider the population’s needs and demands.
At the time of this study, there was no policy to insti-
tute CBD models and guide the implementation efforts
in the Western Cape. Stakeholders were not aware of
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policies in other parts of the world enabling the use of
non-registered sites for distribution of medicines for
chronic diseases and as an interim measure, they devel-
oped standard operating procedures (SOPs), based
loosely on available pharmacy and health regulations.
Stakeholder views on these SOPs varied. As one provin-
cial manager explained:
“… this (CBD) is new … There was, like, really no
definite law to guide the Pharmacy Council. So,
whatever has happened has been an interpretation of
the law by someone (provincial stakeholders) …”
We were informed by a key actor during this study that
some engagement between provincial and national stake-
holders responsible for the policy making process had
commenced by 2014. The South African Pharmacy
Council (SAPC), which is the statutory professional body
for pharmacy, together with the National Department of
Health (NDoH) which has oversight of health activities
and legislation, were cited as the two governance bodies
responsible for drafting legislation. While recognising that
CBD policy development is a national priority and that
the process of policy-making can be slow, stakeholders in-
sinuated that the process has not been altogether trans-
parent. We found there was limited consultation of
frontline HCPs on the issue and that no feedback on pro-
gress of the policy development process was given at this
level. One senior manager had some information on the
process and reported that a task team had been set-up
and was steadily working on developing the policy.
Stakeholder perspectives on the future CBD policy
In general, informants envisaged that the policy will define
organisation of CBD services to ensure the delivery of qual-
ity pharmaceutical services as defined by the Good Phar-
macy Practice (GPP) standards [38]. There were some
shared concerns that some aspects inherent to CBD models
do not meet GPP standards, inter alia, medicines handling
and storage and possible lack of patient counselling.
Some stakeholders justified the current structure of
CBD services while others showed disfavour towards
some aspects of CBD and offered suggestions for im-
proved organisation and structure. Despite varying opin-
ions on what the content of the CBD policy ought to be, a
critical issue that was raised was the need for the policy to
be context specific and pragmatic. There were concerns
that existing CBD models could be jeopardised if the up-
coming policy prescribed the use of qualified personnel
(HCPs) and/or distribution from health sites only. It must
be understood, however, that the call for flexibility is not
akin to accepting sub-standard service. Rather, it is a call
to be realistic regarding what is both feasible and sustain-
able in the local context. As one manager said:
“…they (regulators) need to draft the legislation to
reflect pharmaceutical services as they are delivered in
2015, and going forward not in 20 years ago and in
30 years ago. Medicines are not ordinary commodities.
The integrity of the medicine has to be maintained…
but our request collectively to council (SAPC) has been
could one look at a framework where one could legally
issue the medicines that are not on a health site… and
have a set of norms and standards for the issuing of
medicines … as long as rules and standards are met
and maintained and monitored.”
Furthermore, the call for regulators’ flexibility stemmed
from the simple realisation that more diversification is
required if the province (and indeed the country at large)
is to truly expand ATM. A private-sector pharmacist elab-
orated on this aspect as follows:
“I said to somebody from council (SAPC): we are
trying to put down first world standards which is very
noble, but we are a resource lacking third world,
essentially, third world country. We have a component
of first world, but ninety per cent is third world. We
are a developing country. I hope it gets taken into
consideration, because I think it’s going to make
implementation of a lot of what national health
(insurance) wants to do almost impossible to start.”
The quote above called into question the degree of align-
ment between the province’s and country’s goals of improv-
ing ATM and the focus by professional statutory bodies on
what were sometimes perceived as rigid standards. There
was also a prevailing view that perhaps professional bodies
were minimally consulted in the development of CBD
strategies and that subsequent disagreements are arising be-
tween policy stakeholders:
“…how much dialogue is actually happening between
national, what national (NDOH) is trying to bring
through the National Health Insurance versus what
Pharmacy Council (SAPC) is saying and the statutes
to everybody in terms of best policy. I don’t think they
are on the same page as to what the best practice is.
(private-sector pharmacist)
On a positive note, despite a lack of consensus among
stakeholders on certain issues, there was notable com-
mitment from the WCDoH leadership to engage with
SAPC and eventually align with the future CBD policy.
Stakeholders also anticipated that CBD implementation
could eventually cost more than is currently envisaged if
provinces have to invest in training personnel and adapt-
ing venues to meet requirements for medicine handling
and storage for example.
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Discussion
CBD models are regarded as a useful way to improve
ATM in the Western Cape Province. In this article, we
described a range of formal and informal CBD models
present using the framework by van Olmen et al. [30].
The framework enabled us to illustrate how the config-
uration of the elements in each CBD model could con-
tribute to its effectiveness and furthermore, to illustrate
the interconnections between the CBD models and the
wider health system elements, indicating how policy de-
cisions on each of these elements will likely affect other
elements. For example, the framework argues for the
need to recognise patients’ own contributions to their
personal well-being [30]. Through our research, we
noted demand-driven operations by informal providers
in a context where senior managers were opposed to the
idea. Some differences between formal and informal
models were that the formal models are a health system
response and therefore, at least in theory resourced and
accountable to the system while informal models are
grassroots driven, self-funded and with no accountability
mechanisms to the health system. However, both have
the same goal of improving ATM.
Another key lesson from the application of the frame-
work is that it is the combination of different health
system elements that makes a model work well. For
example, a decision on the human resource cadre(s)
could influence the structure and operational modalities
of CBD models, particularly when task-shifting is
introduced and mechanisms for accountability and qual-
ity assurance become essential. Table 3 summarises what
we identified to be facilitators and barriers associated
with each CBD element in its current form, an approach
we envisage will inform the policy debate.
Despite increased interest in CBD by stakeholders in the
WC, medicines are governed by pharmaceutical policy,
therefore, who handles them and how they are handled
becomes a matter of regulatory interest. This dimension
needs to be carefully navigated to ensure safety of the
population. As there is currently no CBD policy, we
explored how our findings could inform the development
of a future policy, through knowledge of context needs
and demands. Through this study, we have brought the
voices of frontline HCPs to the policy discussion on ATM.
As stated by Gilson & Raphaely, “Policy actors are not just
those officially tasked with policy development; they also
include those with concern for particular policy issues or
likely to be affected by policy developments…” [39]. We
identify HCPs as such because of their important role at
the coal-face of the health services and as such as the ac-
tual implementers of policy.
We identified some lessons from this study which could
inform the policy development process. First, reaching a
consensus requires broad stakeholder consultation as part
of the policy development process, which to our know-
ledge has not yet been conducted in this case. Despite
some stakeholders being aware that the policy develop-
ment process had commenced, we found that consultation
Table 3 Summary of how CBD elements facilitate or constrain CBD implementation
CBD element Facilitators Barriers
Medicines o Centralised dispensing simplifies distribution
process.
oQuality assurance processes must be fulfilled
by HCPs prior to “last mile” distribution;
o Stock-outs of medicines cripples CBD models;
o Non-collected medicines cannot be re-dispensed.
Human resources Community Health Workers o Positive, close relationships with patients
which can facilitate active follow-up
when necessary.
o Not able to conduct quality assurance processes.
HCPs oMissing medicines from patient-ready
parcels can be dispensed manually by
the HCP at the CBD site.
o General shortage of HCPs undermine sustainability
of deploying them to CBD sites.
Informal providers o Demand-driven therefore likely to suit
beneficiary needs.
o No governmental oversight which could
lead to financial exploitation of patients;
o no accountability to professional statutory body
which could compromise quality of
pharmaceutical services.
Infrastructure and logistics o Government vehicles available for
transportation of medicines for some
models.
o Poor transport systems for CHWs causing delays
and posing security and environmental risks to
medicines;
o Availability of venues not always guaranteed.
Patient (population)’s engagement
with CBD models
o Positive patient-patient; patient-provider
relationships;
o Some patients knowledgeable about their
treatment regimen and proactive in
addressing medicine-related
concerns.
o Stigma associated with HIV still a reality.
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and feedback on the progress of the process was not inclu-
sive and that frontline HCPs who are responsible for
implementing policies were not involved. Acknowledging
that policy processes are in essence political, how much
influence actors have might be contingent on their pos-
ition in the political hierarchy, more than their knowledge
and understanding of the issue [40]. Hence in this study,
we have sought to elevate the voice of frontline HCPs,
who possess knowledge and understanding of grassroots
issues. This stakeholder group has been referred to as
“street-level bureaucrats”: they are tasked with policy im-
plementation and often have to balance policy demands
with the realities of their context [41]. Considering their
perspectives during the policy development process could
result in more responsive policies. As echoed by Morrow
(2015), the process of formulating a pharmaceutical policy
is as important as the policy document in ensuring col-
lective ownership [42].
Second, the resistance by some stakeholders to aspects
of CBD corroborates findings in other countries. Indeed,
previous studies have shown that diversion from trad-
itional ways of delivering pharmaceutical services and task
shifting in the pharmaceutical sector in its different forms
has in many instances met with resistance [43, 44]. Experi-
ences of resistance to different CBD models were
documented in Mozambique with the introduction of
self-forming patient groups [19] and in Tanzania with the
implementation of community retail drug shops, but this
changed with time [45]. In Mozambique, as stakeholders
gained knowledge and confidence in the model and the
benefits became apparent, endorsement increased [19]. In
Tanzania, retail drug shops which are a major source of
medicines in rural and underserved areas also initially
faced resistance, then catalysed development of policies.
Of note, the Tanzania model illustrated that even informal
providers can be assisted to comply with regulatory stan-
dards [45]. Whether or not this will become the experi-
ence of providers in our context, remains to be seen.
Implications for future research and the policy agenda
The current provincial [32, 33] and national [4] goals for
UHC in South Africa include both CBD and a commit-
ment to provision of quality services [46], presenting an
opportunity to leverage the existing political window.
However, while the need to develop a policy to govern
CBD activities in South Africa is evident, it is uncertain
what changes the anticipated policy will bring to existing
models. As earlier indicated, many of our informants
hoped that the introduction of policy will not pose a bar-
rier to further implementation of current CBD models.
This has been experienced in other contexts where
innovation in community-based services began outside
of public regulation [47]. We argue that despite the di-
verging stakeholder views, CBD must be assessed within
the lens of what it is endeavouring to achieve - sustain-
able ATM. The World Health Organisation (WHO) has
recommended in other instances that implementing
regulation targeted at innovative models should neither
decelerate the speed at which action is already taking
place nor usher in restrictions that may have a constrain-
ing effect on public health service delivery effort [48]. That
said, there is need to conduct accurate assessments of the
effectiveness of these models and to ensure that they are
implemented in a way that ensures patient safety.
In addition, informal models present an additional set
of challenges, i.e. the lack of accountability mechanisms
and the potential financial burden on patients caused by
paid services. While it is true that there are high poverty
levels in this context, the paid option is voluntary. Per-
haps the critical question is: “Why do patients choose to
pay for medicines delivery when they can get a ‘free’ ser-
vice?”. Since we did not interview patients paying for
this service as part of this study, we can only speculate
that the parallel system tends to thrive because there is
an opportunity cost related to the informal system, i.e. it
offers benefits (e.g. the convenience of not having to take
time off work, which could result in a cost of a different
kind) that might not be present within the formal ‘free’
system. Future studies could assess whether this system
imposes a financial or any other burden on patients. If it
does, but has other benefits to patients, the next issue is
whether the government can lend support to informal
providers so that they operate at a lower or no cost to
patients.
Finally, further research is required to identify how
CBD models have been implemented in other settings
and their cost to health systems. Therefore, as a follow-
up study, we have designed a scoping review which aims
to obtain systematic evidence about design and imple-
mentation of CBD models in low resource settings and
hard to reach populations in high income countries. We
intend to assess whether the issues raised in this article
were identified and if so, how they were or could be
managed or overcome.
Study limitations
A limitation of this study was the adoption of the analyt-
ical framework after data collection; therefore, not all
components were addressed equally during interviews
with stakeholders. This is particularly true for monitor-
ing and evaluation of CBD models, an area that requires
attention in future studies. Second, the lack of accurate
data on outcomes imposed some limitation.
Conclusion
Improving medicines delivery is integral to attaining
UHC and the introduction of CBD in South Africa is
one mechanism to achieve this goal. To achieve the
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intended benefits of CBD, frontline HCPs should be con-
sulted in policy development and consideration should be
given to similar models in other contexts. Further research
will seek to contribute towards evidence-based develop-
ment of policy and service delivery guidelines for CBD
activities in South Africa within the frameworks of
pharmaceutical policy and practice.
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